Table 1.
Clinical trials of CXCR4 inhibitors in acute myeloid leukemia
| CXCR4 inhibitors | Combined regimens | Phase | Patient population | Sponsor | ClinicalTrials.gov identifier |
|---|---|---|---|---|---|
| Plerixafor | Mitoxantrone + Etoposide + Cytarabine | 1/2 | rrAML | Washington University | NCT00512252 |
| G-CSF + Mitoxantrone + Etoposide + Cytarabine | 1/2 | rrAML | Washington University | NCT00906945 | |
| Decitabine | 1 | Untreated elderly AML | Cornell University | NCT01352650 | |
| G-CSF + Sorafenib | 1 | rrAML with FLT3-ITD | M.D. Anderson Cancer Center | NCT00943943 | |
| Daunorubicin + Cytarabine | 1 | Untreated AML | Genzyme/Sanofi | NCT00990054 | |
| Daunorubicin + Clofarabine or Cytarabine | 1 | Untreated elderly AML | Cardiff University | NCT01236144 | |
| Cytarabine + Etoposide | 1 | rrAML | Emory | NCT01319864 | |
| Clofarabine | 1/2 | Untreated elderly AML | M.D. Anderson Cancer Center | NCT01160354 | |
| Fludarabine + Idarubicin + Cytarabine + G-CSF | 1/2 | rrAML | PETHEMA | NCT01435343 | |
| BL-8040 | Mitoxantrone + Etoposide + Cytarabine | 1 | rrAML | BioLineRx | NCT01838395 |
| Cytarabine as consolidation | AML in remission | Dr. Petra Tschanter | NCT02502968 | ||
| LY2510924 | Idarubicin + Cytarabine | 1 | rrAML | M.D. Anderson Cancer Center | NCT02652871 |
| Ulocuplum-ab | Low-dose cytarabine | 1 | Untreated AML, unfit for intensive induction | Bristol-Myers Squibb | NCT02305563 |
| Mitoxantrone + Etoposide + Cytarabine | 1 | rrAML | Bristol-Myers Squibb | NCT01120457 |
rrAML, relapsed/refractory AML; G-CSF, granulocyte colony-stimulating factor; AML, acute myeloid leukemia; FLT3-ITD, Fms-like tyrosine kinsase-3 with internal tandem duplication mutation.